CLINICAL_TRIALS
trial_result
· 2020-10-30
Clinical Trial Update: Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) [Phase 2]
Summary
Phase 2 trial of GTx-024 in androgen receptor–positive triple negative breast cancer was terminated; results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GTx | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-10-30